Novo Nordisk reported that CagriSema, its next-generation obesity drug combining semaglutide and cagrilintide, achieved 25% average weight loss in women across two post-study analyses released Tuesday. The company says the results strengthen the case for the injection to outperform its existing GLP-1 drug Wegovy.

In an analysis of roughly 2,300 women with obesity or overweight status, CagriSema produced 25% weight loss at 68 weeks compared with 3% for placebo, assuming all patients remained on treatment without interruptions. A second analysis of about 1,900 women stratified by menopausal status showed weight loss of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women at 68 weeks, versus approximately 2% across all menopause groups taking placebo under the same adherence assumption.

Both analyses also linked CagriSema to reductions in abdominal fat measured by waist circumference across all women studied and within menopause subgroups. Novo noted the women-specific results suggest slightly higher weight loss than the broader Phase 3 trial population experienced, despite women comprising about 67% of the roughly 3,400 total trial participants.

Novo said further work is needed to confirm the hypotheses underlying the two post-study analyses. The company expects CagriSema to launch in early 2027. Novo's clinical development interim head Michelle Skinner Moore said exploring CagriSema across "the reproductive lifespan" matters because many women experience weight gain during menopause as declining estrogen slows metabolism.

The combination targets the amylin pathway, a hormone mechanism released alongside insulin in the pancreas that helps regulate hunger and fullness signals. Novo and competitor Eli Lilly have built new obesity treatments around amylin to create revenue streams beyond existing GLP-1 drugs.

Wall Street has shown limited enthusiasm for CagriSema after previous late-stage results disappointed investors due to weight loss efficacy below expectations. Novo maintains the drug is effective and sufficiently differentiated. Analysts estimate CagriSema will generate $11.84 billion in obesity-specific sales by 2028, according to FactSet consensus.